Cargando…
Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival
Patients diagnosed with metastatic soft-tissue sarcoma (STS) have a poor prognosis. Additionally, after failure of first-line therapy, there are relatively few treatment options from which to choose. The novel tubulin-binding drug, eribulin, with a unique mechanism of action from taxanes or vinca al...
Autores principales: | Thomas, Colin, Movva, Sujana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024770/ https://www.ncbi.nlm.nih.gov/pubmed/27672333 http://dx.doi.org/10.2147/OTT.S93517 |
Ejemplares similares
-
Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022) -
Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018) -
Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016) -
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017) -
Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
por: Tsuchihashi, Kenji, et al.
Publicado: (2020)